Loading
Prostate Cancer Treatment and Research / Epigenetics and DNA Methylation · Journal article
Genome Biology · July 22, 2026
Raises a question worth testing. It does not answer one.
This mechanistic study identifies 3,216 prostate cancer-specific putative enhancers and demonstrates through chromatin profiling and CRISPR perturbations that enhancers form hierarchical, multi-connected chromatin interaction hubs at a representative locus. Central enhancers control hub-wide activity and gene expression, while redundant enhancers are functionally compensated, revealing a model of coordinated enhancer function; however, the work is limited to one locus and lacks clinical validation.
Integrated multi-omic mechanistic study with CRISPR perturbations and chromatin interaction profiling. Prostate cancer cells and normal prostate cells. Specific cell types, lines, or patient-derived materials not specified in abstract.. Intervention: CRISPR/Cas9 deletion of individual enhancers within cancer-specific chromatin interaction hubs at chr6q24.1 locus. Compared with: Normal prostate cells; unperturbed cancer cells; cancer cells with different enhancer deletions (central vs. redundant).
3,216 high-confidence prostate cancer-specific putative enhancers identified by integration of 201 H3K27ac ChIP-seq datasets Ultra-high-resolution chromatin interaction profiling reveals cancer-specific, highly nested enhancer–promoter interactions coalescing into multi-connected hub absent in normal prostate cells at chr6q24.1 locus CRISPR deletion of central enhancer collapses hub-wide enhancer activities and architecture, leading to downregulation of target genes, impaired proliferation, and reduced clonogenic growth
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This work is primarily mechanistic and does not directly inform current clinical practice. The hierarchical enhancer model may eventually enable precision therapies targeting specific enhancer classes, but validation in animal models and clinical trials would be required before therapeutic translation.
Mechanistic study using CRISPR perturbations and chromatin profiling to explore enhancer function in prostate cancer, raising questions about hierarchical gene regulation but lacking clinical endpoints or validated therapeutic translation.
As stated by the source record.
Quoted from the source exactly as published.
This work is primarily mechanistic and does not directly inform current clinical practice. The hierarchical enhancer model may eventually enable precision therapies targeting specific enhancer classes, but validation in animal models and clinical trials would be required before therapeutic translation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
BACKGROUND: The transcription process is controlled by non-coding regulatory elements, more than 70% of which are putative enhancers. These enhancers comprise over 600,000 regions and are marked by histone modifications. However, the mechanisms by which altered enhancers in cancer cooperate within the three-dimensional chromatin architecture to drive oncogenic programs remain poorly understood. RESULTS: By integrating 201 H3K27ac ChIP-seq datasets from prostate, we identify 3,216 high-confidence prostate cancer-specific putative enhancers. Ultra-high-resolution chromatin interaction profiling by Region Capture Micro-C at a representative chr6q24.1 locus reveals that these enhancers form cancer-specific, highly nested interactions with promoters that coalesce into a multi-connected hub absent in normal prostate cells. CRISPR/Cas9 perturbations of these enhancers, examined one by one, distinguish enhancer classes within the hub. Deletion of a central enhancer collapses hub-wide enhancer activities and architecture, leading to the downregulation of target genes, impaired proliferation, and reduced clonogenic growth. In contrast, deletion of a redundant enhancer results in minimal transcriptional changes, as neighboring enhancers rescue cancer signaling through compensatory architectural rewiring that strengthens alternative enhancer-promoter interactions. We also observe that FOXA1, a pioneer transcription factor activated in prostate cancer, directly binds to these enhancers and regulates distinct enhancer classes, leading to varying degrees of chromatin accessibility and gene expression changes. CONCLUSIONS: These findings suggest that enhancers function in a coordinated manner, forming multi-connected cancer-specific chromatin interaction hubs, with distinct enhancer classes contributing differently to gene regulation. This study advances our ability to modulate gene expression in a cell type-specific manner, opening new avenues for precision therapies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.